Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

Por Ali, Ayad K
Publicado em 2011

Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting

Por Ali, Ayad K, Hartzema, Abraham G
Publicado em 2012

Impact of lymphopenia on COVID-19 infection severity

Por Ali Ayad Tareq, Naqaa Majeed Hameed, Tabarak Saleem Abdulshaheed
Publicado em 2022-01-01

Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes

Por Simeone, Jason C, Bae, Jay P, Hoogwerf, Byron J, Li, Qian, Haupt, Axel, Ali, Ayad K, Boardman, Marilyn K, Nordstrom, Beth L
Publicado no Clin Epidemiol (2017)

CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer

Por Dai, Meiou, Zhang, Chenjing, Ali, Ayad, Hong, Xinyuan, Tian, Jun, Lo, Chieh, Fils-Aimé, Nadège, Burgos, Sergio A., Ali, Suhad, Lebrun, Jean-Jacques
Publicado no Sci Rep (2016)